Figure 2
KaplanâMeier estimates for TTP. TTP is significantly longer in EGF100642 HER2-positive patients vs EGF104911 patients (median TTP for EGF100642=16.3 weeks; EGF104911=8.4 weeks; P=0.0212).
Figure 2 | British Journal of Cancer
KaplanâMeier estimates for TTP. TTP is significantly longer in EGF100642 HER2-positive patients vs EGF104911 patients (median TTP for EGF100642=16.3 weeks; EGF104911=8.4 weeks; P=0.0212).
